Healthcare [ 3/11 ] | Biotechnology [ 34/154 ]
US | NASDAQ | Stock
Reported Date | EPSChange YoY | EstimateSurprise |
---|---|---|
Nov 14, 22 | -0.26
Increased by
+96.71%
|
-0.23
Decreased by
-13.04%
|
Aug 15, 22 | -0.25 | -0.24
Decreased by
-4.17%
|
May 16, 22 | -0.23 | -0.17
Decreased by
-35.29%
|
Nov 15, 21 | -0.10 | -0.17
Increased by
+41.18%
|
Aug 16, 21 | -7.91 | -4.56
Decreased by
-73.46%
|
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Sep 30, 22 | 0.00
Decreased by
N/A%
|
-10.71 M
Decreased by
-174.47%
|
Decreased by
N/A%
Decreased by
N/A%
|
Jun 30, 22 | 0.00
Decreased by
N/A%
|
-10.15 M
Increased by
+83.46%
|
Decreased by
N/A%
Decreased by
N/A%
|
Mar 31, 22 | 0.00
Decreased by
N/A%
|
-9.13 M
Increased by
+66.19%
|
Decreased by
N/A%
Decreased by
N/A%
|
Dec 31, 21 | 0.00
Decreased by
-100.00%
|
-8.35 M
Decreased by
-235.30%
|
Decreased by
N/A%
Decreased by
N/A%
|
Sep 30, 21 | 0.00
Decreased by
-100.00%
|
-3.90 M
Decreased by
-91.74%
|
Decreased by
N/A%
Decreased by
N/A%
|
Jun 30, 21 | 0.00
Decreased by
-100.00%
|
-61.36 M
Decreased by
-2.90 K%
|
Decreased by
N/A%
Decreased by
N/A%
|
Mar 31, 21 | 0.00 - | -27.00 M - |
Decreased by
N/A%
-
|
Sep 30, 20 | 730.00 K - | -2.49 M - |
Decreased by
-341.10%
-
|
Rank | ETF | Shares | Market Value | Weight % in ETF |
---|
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.